Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Completion of sale of subsidiary

17 Jan 2019 13:54

RNS Number : 4186N
Craven House Capital PLC
17 January 2019
 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Craven House Capital plc

 

("Craven House" or the "Company")

 

Completion of sale of subsidiary to LM Funding America Inc.

 

 

The Company announces that it has completed the sale of its wholly owned subsidiary, IIU Inc., ("IIU") (a medical insurance broker) to LM Funding America Inc. ("LMFA") for a total purchase price of approximately $5.1 million.

 

The purchase price has been revised from that previously announced as certain other assets owned by IIU are no longer being acquired by LMFA and instead are being transferred to IIU's parent company, Craven House Capital North America LLC (a wholly owned subsidiary of the Company). In the Company accounts for the year ended 30 May 2018, IIU carried a value of approximately £2.4m and, in 2017, generated approximately $500,000 in adjusted pre-tax income.

 

Under the terms of the transaction, LMFA will acquire 100% of the outstanding stock of IIU. The consideration will comprise cancellation by LMFA of all principal and accrued interest of a Promissory Note issued to LMFA for principal indebtedness of approximately $1.5 million and the issuance of Convertible Promissory Note ("Convertible Note") for the balance of the purchase price of approximately $3.6 million.

 

The Convertible Note shall bear simple interest at 3% per annum. The Convertible Note shall be due and payable 360 days following the completion of the transaction. The note is payable at Craven's option, subject to LMFA shareholder approval, in common stock of LMFA at a conversion price of $2.41 per share at any time on or after the first meeting of shareholders of LMFA to occur in 2019. In the event that the entire principal is converted to shares, this will represent approximately 1.5 million new common shares in LMFA.

 

As previously announced, this transaction therefore provides Craven with the option to significantly increase its shareholding in LMFA, following the previously announced acquisition of 640,000 shares in LMFA in November.

 

~ Ends ~

 

 

For further information please contact:

 

Craven House Capital Plc

Mark Pajak

www.Cravenhousecapital.com

 

Tel: 0203 286 8130

 

 

SI Capital

Broker

Nick Emerson

www.sicapital.co.uk

Tel: 01483 413500

 

SPARK Advisory Partners Limited

Nominated Adviser

Matt Davis/Mark Brady

www.Sparkadvisorypartners.com

 

Tel: 0203 368 3550

 

 

 

About Craven House Capital:

 

The Company's Investing Policy is to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets globally in any geographic jurisdiction. The company will invest in both developed and developing markets providing long term patient capital and is often involved in special situations, restructuring, expansion and turn around investments in crisis and transitioning economies.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DISCKODPNBKDDDD

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.